Clinical Trial Update: TAK-954 in Critically Ill Participants With Enteral Feeding Intolerance (EFI) [Phase 2]

View source ↗

Summary

Phase 2 trial of TAK-954 in critically ill patients with enteral feeding intolerance was terminated; results posted in 2019.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Critical Illness
• Enteral Feeding Intolerance
• Enteral Nutrition

Drugs mentioned

• TAK-954

Snippet

Sponsor: Millennium Pharmaceuticals, Inc. | Conditions: Critical Illness, Enteral Nutrition | Phase 2 | Status: TERMINATED | Results posted: 2019-09-24